Since FADS1 knockdown activated STING-mediated interferon signaling in AML cells and that STING agonists have shown antileukemia potential (14, 16), we assessed how CRISPR/Cas9-mediated deletion of STING (STINGKO; Fig. S4F) impacted the antileukemia effects of FADS1 inhibition. Here, FADS1 is linked to acute myeloid leukemia.